Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijnsma, Kioa Lente, ter Heine, Rob, Moes, Dirk Jan A. R., Langemeijer, Saskia, Schols, Saskia E. M., Volokhina, Elena. B., van den Heuvel, Lambertus P., Wetzels, Jack F. M., van de Kar, Nicole C. A. J., Brüggemann, Roger J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584251/
https://www.ncbi.nlm.nih.gov/pubmed/30758736
http://dx.doi.org/10.1007/s40262-019-00742-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584251/
https://www.ncbi.nlm.nih.gov/pubmed/30758736
http://dx.doi.org/10.1007/s40262-019-00742-8

Ejemplares similares